상세 보기
Once-daily dosing of amikacin for treatment of <i>Mycobacterium abscessus</i> lung disease
- Lee, H.;
- Sohn, Y. M.;
- Ko, J. Y.;
- Lee, S-Y.;
- Jhun, B. W.;
- ... Park, H. Y.;
- ... Jeon, K.;
- ... Moon, I. J.;
- 외 6명
WEB OF SCIENCE
25SCOPUS
23초록
SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE: To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS: With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (C-max), the C-max target of 55-65 mu g/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONCLUSION: Our results suggest that once-daily AMK for 4 weeks with a target C-max of 55-65 mu g/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.
키워드
- 제목
- Once-daily dosing of amikacin for treatment of <i>Mycobacterium abscessus</i> lung disease
- 저자
- Lee, H.; Sohn, Y. M.; Ko, J. Y.; Lee, S-Y.; Jhun, B. W.; Park, H. Y.; Jeon, K.; Kim, D. H.; Kim, S-Y.; Choi, J. E.; Moon, I. J.; Shin, S. J.; Park, H. J.; Koh, W-J.
- 발행일
- 2017-07
- 유형
- Article
- 권
- 21
- 호
- 7
- 페이지
- 818 ~ 824